News
Repsol Announces Share Buyback Plan and Reports Q2 Financial Results
Repsol announces share buyback program and reports Q2 financial results showing decreased net profit. Sales decline attributed to lower energy prices.
Stock Futures Point Higher After Fed Raises Interest Rates
Stock futures rise after Fed raises interest rates. Meta Platforms posts strong Q2 earnings, Chipotle faces revenue shortfall, ServiceNow exceeds expectations,...
Keurig Dr Pepper Reports Significant Profit Growth in Q2
Keurig Dr Pepper reports a significant profit growth in Q2, with net profit more than doubling and sales increasing following a price hike. Chairman and CEO exp...
Asensus Surgical Announces Direct Offering
Asensus Surgical announces agreement for direct offering, selling 23.8 million shares and warrants. Expects to generate $10 million in proceeds for corporate pu...
NatWest to Report Second-Quarter Results
NatWest is set to reveal its second-quarter results, including operating pretax profit, net profit, and total income. Key metrics to observe include net interes...
Boeing's Quarterly Report: Positive Cash Flow Despite Ongoing Losses
Boeing's quarterly report reveals positive cash flow despite ongoing losses. The disparity between earnings and cash flow is attributed to accrual-based account...
Ford Reports Strong Q2 Results and Raises 2023 Outlook
Ford Motor Co. reported strong Q2 results and raised its outlook for 2023, with a significant increase in profit and revenue. The company saw a 12% increase in...
Maruti Suzuki India to Report Q1 Results
Maruti Suzuki India, a leading automotive manufacturer, will report its Q1 results. Net profit forecasted to more than double and revenue to increase by 20%. In...
Church & Dwight Beats Revenue and Profit Expectations in Q2
Church & Dwight surpasses revenue and profit expectations in Q2 with higher sales and raised prices. Outlook shows strong growth projections.
Biogen to Acquire Reata Pharmaceuticals for $7.3 Billion
Biogen Inc. will acquire Reata Pharmaceuticals Inc. in a $7.3 billion cash deal, enhancing their neurologic disease treatment offerings.